Afferent Pharmaceuticals racks up $55 mln Series C

San Mateo, California-based Afferent Pharmaceuticals, a developer of drugs that treat neurogenic respiratory, urologic and pain disorders, has closed $55 million in Series C funding. Fidelity Management & Research Company led the round with participation from other investors that included Jennison Associates LLC (on behalf of certain clients), New Leaf Ventures, Partner Fund Management, Redmile Group, Tekla Healthcare Investors and Tekla Life Science Investors.


Scanadu scores $35 mln Series B

Silicon Valley-based medical tech company Scanadu Inc has raised $35 million in Series B funding. Fosun International and Tencent Holdings Limited led the round with participation from China Broadband Capital, Iglobe Partners, Relay Ventures, Redmile Group, Ame Cloud Ventures and Three Leaf Ventures. In conjunction with the funding, Dr. Robert Harrington and Ezra Kucharz have been added to Scanadu’s board of directors.

Jounce Therapeutics picks up $56 mln Series B

Cambridge, Massachusetts-based Jounce Therapeutics, which is focused on discovering and developing cancer immunotherapies, has closed $56 million in Series B funding. The investors included Wellington Management Company, Redmile Group, Nextech Invest, Pharmstandard International, S.A., Cormorant Asset Management, Omega Funds, Casdin Capital and Foresite Capital Management.


Redmile Group leads Series B round for Scioderm

Scioderm, a Durham, NC-based pharmaceutical firm, has closed $20 million in Series B funding. Redmile Group led the round with participation from other investors that included Morganthaler Ventures and Technology Partners. J.P. Morgan Securities was the placement agent on the transaction.


Blueprint Medicines ropes in $50 mln

Blueprint Medicines has raised $50 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Wellington Management Company, RA Capital, Tavistock Life Sciences, Perceptive Advisors, Sabby Capital, Cowen Investments, Redmile Group, Fidelity Biosciences and Third Rock Ventures. Based in Cambridge, Mass., Blueprint Medicines is a developer of kinase inhibitors for genomically defined cancers.


One Medical raises a healthy $40 mln in growth funding

One Medical Group, a San Francisco-based provider of healthcare services, has raised $40 million in growth capital in a round led by Redmile Group. Current investors also participated in the round. One Medical previously raised $76.5 million in funding from Benchmark Capital, DAG Ventures, Oak Investment Partners, Google Ventures and Maverick Capital.


Health diagnostics ‘tricorder’ maker Scanadu raises $10.5 mln from Relay Ventures, Tony Hsieh, Jerry Yang

Scanadu, a developer of personalized health electronics, has raised $10.5 million in Series A funding that was led by Relay Ventures. Other investors include Tony Hsieh’s VegasTechFund, Jerry Yang’s Ame Cloud Venture, Broe Group, Mindful Investors and Redmile Group. Scanadu previously raised $1.7 million in a crowdfunding campaign on the Indiegogo platform that was launched in May. The company has now raised $14.7 million in funding to date. Scanadu, which is based at the NASA Ames Research Center in Moffett Field, Calif., makes a medical sensor device inspired by the tricorder on “Star Trek” to diagnose information about a patient, such as cardiovascular health. Scanadu founder and CEO Walter De Brouwer told peHUB that the company expects to begin shipping in March.

Castlight Appoints Driscoll as President

Castlight Health, a provider of health care transparency solutions for employers and payers, has appointed John Driscoll as president. Castlight Health is headquartered in San Francisco and backed by investors including Allen & Company, Cleveland Clinic, Maverick Capital, Morgan Stanley Investment Management, Oak Investment Partners, Redmile Group, T. Rowe Price, U.S. Venture Partners, Venrock, Wellcome […]

Oxford Nanopore Closes on $41M

Oxford Nanopore Technologies Ltd., a UK-based developers of nanopore technology, has sealed 25 million pounds ($41 million) in new funding. Lansdowne Partners, IP Group, Invesco Perpetual, Redmile Group, Illumina and other undisclosed investors participated in the round. The company had previously raised 49 million pounds. Oxford Nanopore was formed in 2005, and will use the money for continued development.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget